SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:5257028c-e168-443e-a6ea-21fde282e043"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:5257028c-e168-443e-a6ea-21fde282e043" > Efficacy assessment...

  • Cullen, Nicholas C.Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups (författare)

Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology : a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • 2024

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:5257028c-e168-443e-a6ea-21fde282e043
  • https://lup.lub.lu.se/record/5257028c-e168-443e-a6ea-21fde282e043URI
  • https://doi.org/10.1016/j.ebiom.2023.104923DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:154606349URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Background: Tau pathology correlates with and predicts clinical decline in Alzheimer's disease. Approved tau-targeted therapies are not available. Methods: ADAMANT, a 24-month randomised, placebo-controlled, parallel-group, double-blinded, multicenter, Phase 2 clinical trial (EudraCT2015-000630-30, NCT02579252) enrolled 196 participants with Alzheimer's disease; 119 are included in this post-hoc subgroup analysis. AADvac1, active immunotherapy against pathological tau protein. A machine learning model predicted likely Amyloid+Tau+ participants from baseline MRI. Statistical methods: MMRM for change from baseline in cognition, function, and neurodegeneration; linear regression for associations between antibody response and endpoints. Results: The prediction model achieved PPV of 97.7% for amyloid, 96.2% for tau. 119 participants in the full analysis set (70 treatment and 49 placebo) were classified as A+T+. A trend for CDR-SB 104-week change (estimated marginal means [emm] = −0.99 points, 95% CI [−2.13, 0.13], p = 0.0825]) and ADCS-MCI-ADL (emm = 3.82 points, CI [−0.29, 7.92], p = 0.0679) in favour of the treatment group was seen. Reduction was seen in plasma NF-L (emm = −0.15 log pg/mL, CI [−0.27, −0.03], p = 0.0139). Higher antibody response to AADvac1 was related to slowing of decline on CDR-SB (rho = −0.10, CI [−0.21, 0.01], p = 0.0376) and ADL (rho = 0.15, CI [0.03, 0.27], p = 0.0201), and related to slower brain atrophy (rho = 0.18–0.35, p < 0.05 for temporal volume, whole cortex, and right and left hippocampus). Conclusions: In the subgroup of ML imputed or CSF identified A+T+, AADvac1 slowed AD-related decline in an antibody-dependent manner. Larger anti-tau trials are warranted. Funding: AXON Neuroscience SE.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Novak, PetrAxon Neuroscience SE (författare)
  • Tosun, DuyguSan Francisco Veterans Administration Medical Center,University of California, San Francisco (författare)
  • Kovacech, BranislavAxon Neuroscience SE (författare)
  • Hanes, Jozef (författare)
  • Kontsekova, Eva (författare)
  • Fresser, MichalAxon Neuroscience SE (författare)
  • Ropele, StefanMedical University of Graz (författare)
  • Feldman, Howard H. (författare)
  • Schmidt, ReinholdMedical University of Graz (författare)
  • Winblad, BengtKarolinska Institutet,Karolinska University Hospital (författare)
  • Zilka, NorbertAxon Neuroscience SE (författare)
  • Klinisk minnesforskningForskargrupper vid Lunds universitet (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:EBioMedicine992352-3964

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy